BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Canta F, Marrone R, Bonora S, D'Avolio A, Sciandra M, Sinicco A, De Rosa FG, Di Perri G. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother. 2005;55:280-281. [PMID: 15650005 DOI: 10.1093/jac/dkh516] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, Difrancesco R, Morse GD. Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2007;29:560-5. [DOI: 10.1097/ftd.0b013e31806db8ae] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Lin H, Wu LJ, Guo SQ, Chen RL, Fan JR, Ke B, Pan ZQ. Dynamic monitoring of serum liver function indexes in patients with COVID-19. World J Clin Cases 2021; 9(7): 1554-1562 [PMID: 33728299 DOI: 10.12998/wjcc.v9.i7.1554] [Reference Citation Analysis]
3 Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, Dorigatti F, Soldarini A, Lazzarin A, Castagna A. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother 2005;56:790-2. [PMID: 16143711 DOI: 10.1093/jac/dki314] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
4 Levy C, Lassailly G, Parmentier E, Duburcq T, Mathurin P, Poissy J. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. Am J Gastroenterol 2020;115:1716-8. [PMID: 32858566 DOI: 10.14309/ajg.0000000000000828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Ertas YN, Mahmoodi M, Shahabipour F, Jahed V, Diltemiz SE, Tutar R, Ashammakhi N. Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19). Emergent Mater 2021;:1-21. [PMID: 33748672 DOI: 10.1007/s42247-021-00165-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Peng JZ, Pulido F, Causemaker SJ, Li J, Lorenzo A, Cepeda C, García Cabanillas JA, DaSilva B, Brun SC, Arribas J. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006;46:265-74. [PMID: 16490802 DOI: 10.1177/0091270005284853] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
7 Molt?? J, Valle M, Blanco A, Negredo E, Delavarga M, Miranda C, Miranda J, Domingo P, Vilar?? J, Tural C, Costa J, Barbanoj MJ, Clotet B. Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment: Influence of Liver Fibrosis. Clinical Pharmacokinetics 2007;46:85-92. [DOI: 10.2165/00003088-200746010-00005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
8 Micheli V, Regazzi M, Dickinson L, Meraviglia P, Villani P, Khoo SH, Viganò P, Cordier L, Cusato M, Duca P, Orlando G, Rizzardini G, Back DJ, Cargnel A. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit 2008;30:306-13. [PMID: 18520602 DOI: 10.1097/FTD.0b013e318177209e] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
9 Torti C, Lapadula G, Uccelli MC, Quiros-Roldan E, Regazzi M, Ladisa N, Micheli V, Orani A, Patroni A, Caputo SL, Tirelli V, Di Giambenedetto S, Cologni G, Costarelli S, Gargiulo F, Manca N, Carosi G; RADAR Study Group of MASTER Cohort. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents 2007;29:185-90. [PMID: 17011754 DOI: 10.1016/j.ijantimicag.2006.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
10 Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020;72:1479-508. [PMID: 32889701 DOI: 10.1007/s43440-020-00155-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 43.5] [Reference Citation Analysis]
11 Alauddin, Chaturvedi S, Malik MY, Azmi L, Shukla I, Naseem Z, Rao C, Agarwal NK. Formononetin and biochanin A protects against ritonavir induced hepatotoxicity via modulation of NfκB/pAkt signaling molecules. Life Sciences 2018;213:174-82. [DOI: 10.1016/j.lfs.2018.10.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
12 Mehta M, Prasher P, Sharma M, Shastri MD, Khurana N, Vyas M, Dureja H, Gupta G, Anand K, Satija S, Chellappan DK, Dua K. Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis. Med Hypotheses 2020;144:110254. [PMID: 33254559 DOI: 10.1016/j.mehy.2020.110254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
13 Han H, He Y, Hu J, Lau R, Lee H, Ji C. Disrupted ER-to-Golgi Trafficking Underlies Anti-HIV Drugs and Alcohol-Induced Cellular Stress and Hepatic Injury. Hepatol Commun. 2017;1:122-139. [PMID: 28626835 DOI: 10.1002/hep4.1030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Cusato J, Allegra S, Massano D, De Francia S, Piga A, D'Avolio A. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 2015;15:263-71. [PMID: 25348619 DOI: 10.1038/tpj.2014.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
15 Gupta NK, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28:1021-1041. [PMID: 18671777 DOI: 10.1111/j.1365-2036.2008.03822.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
16 Satsangi S, Gupta N, Kodan P. Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. J Clin Transl Hepatol 2021;9:436-46. [PMID: 34221930 DOI: 10.14218/JCTH.2020.00174] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007;11:615-39, vii-viii. [PMID: 17723923 DOI: 10.1016/j.cld.2007.06.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
18 D’Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014;69:3061-3066. [PMID: 24997317 DOI: 10.1093/jac/dku234] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
19 Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005;56:273-6. [PMID: 15994247 DOI: 10.1093/jac/dki209] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
20 . Current awareness: Pharmacoepidemiology and drug safety: Current Awareness. Pharmacoepidem Drug Safe 2005;14:i-xii. [DOI: 10.1002/pds.1030] [Reference Citation Analysis]
21 Batteux B, Bodeau S, Gras-Champel V, Liabeuf S, Lanoix JP, Schmit JL, Andréjak C, Zerbib Y, Haye G, Masmoudi K, Lemaire-Hurtel AS, Bennis Y. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. Br J Clin Pharmacol 2021;87:1547-53. [PMID: 32692462 DOI: 10.1111/bcp.14489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 De Nicolò A, Simiele M, Calcagno A, Abdi AM, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. Antimicrob Agents Chemother 2014;58:4042-7. [PMID: 24798279 DOI: 10.1128/AAC.00104-14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
23 Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells 2021;10:1263. [PMID: 34065305 DOI: 10.3390/cells10051263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Agnesod D, De Nicolò A, Simiele M, Mohamed Abdi A, Boglione L, Di Perri G, D'Avolio A. Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. J Pharm Biomed Anal 2014;90:119-26. [PMID: 24366212 DOI: 10.1016/j.jpba.2013.11.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
25 Calza L, Mosca L, Pocaterra D, Piergentili B, Colangeli V, Manfredi R, Erario A, Grossi G, Verucchi G, Viale P. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. Eur J Clin Pharmacol 2011;67:143-9. [PMID: 20878151 DOI: 10.1007/s00228-010-0904-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Front Immunol 2020;11:1991. [PMID: 32903476 DOI: 10.3389/fimmu.2020.01991] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
27 Khaykin P, Kotzerke P, Stephan C, Nisius G, Bickel M, Haberl A, Stürmer M, Kurowski M, Brodt R, von Hentig N. Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment. Therapeutic Drug Monitoring 2014;36:192-201. [DOI: 10.1097/ftd.0b013e3182a28c6a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Deng J, Zhou F, Hou W, Heybati K, Ali S, Chang O, Silver Z, Dhivagaran T, Ramaraju HB, Wong CY, Zuo QK, Lapshina E, Mellett M. Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis. Future Virology. [DOI: 10.2217/fvl-2021-0066] [Reference Citation Analysis]
29 Chihrin S, Antoniou T, Raboud J, Shen S, Govan V, Fletcher D, Rachlis A, Kovacs C, Crouzat F, Tilley D, Chang B, Saskin R, Loutfy MR. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy. AIDS Patient Care STDS 2007;21:469-78. [PMID: 17651028 DOI: 10.1089/apc.2006.0113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
30 Dominguez S, Ghosn J, Peytavin G, Guiguet M, Tubiana R, Valantin MA, Murphy R, Bricaire F, Benhamou Y, Katlama C. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. Journal of Antimicrobial Chemotherapy 2010;65:2445-9. [DOI: 10.1093/jac/dkq320] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]